ALPS Global Holding Berhad
ALPS Global Holding Berhad is a Kuala Lumpur-based integrated biotechnology group operating cell and gene therapy manufacturing (CelestiaLab), genomic testing (MyGenome), medical and wellness services, stem cell supplements, and healthcare financial solutions, serving individual patients, medical tourists, and institutional clients in Southeast Asia following its October 2025 Nasdaq listing.
- Company typePublic
- Founded2015
- HeadquartersKuala Lumpur, Malaysia
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What ALPS Global Holding Berhad does
ALPS Global Holding Berhad is a Kuala Lumpur-based, fully integrated biotechnology research, medical, and wellness services company that operates across predictive, preventive, and precision medicine. Through its wholly-owned subsidiaries, the group runs a cGMP-certified cell and gene therapy facility (CelestiaLab), an MS ISO 15189:2022 accredited molecular laboratory (MyGenome) for whole genome sequencing and related tests, a medical diagnostic and treatment centre (ALPS Medical Centre), a consumer stem-cell supplement brand (Célébre), a healthcare financial solutions unit (ALPSCap), and a vaccine-focused subsidiary (MontLife). Core technology assets include a patent-pending antibody-free NK cell culture protocol (Malaysian patent application PI2025002484) that enables cost-effective, large-scale production of autologous natural killer cells, alongside mesenchymal stem cell (MSC) and induced pluripotent stem cell (iPSC) capabilities.
The company monetizes through professional services across genomic testing and clinical care, one-time licenses/sales of GMP-grade cellular products and stem cell supplements, and managed services via ALPSCap's healthcare financial solutions for corporations, governments, and high-net-worth individuals. Go-to-market combines direct medical service delivery at its Kuala Lumpur and Genting Highlands facilities, medical tourism channels targeting international patients, and B2B partnerships with universities and government institutions, with a stated shift toward captive insurance models and university-affiliated programmes post-Nasdaq listing. Customer segments include patients seeking advanced treatments typically excluded from conventional healthcare, health-conscious individuals pursuing preventive genomic screening, international medical tourism clients, and corporate/institutional buyers of integrated health-wealth solutions.
Following a business combination with Globalink Investment Inc., the US parent (Alps Group Inc.) began trading on Nasdaq under ticker ALPS on October 31, 2025, at an implied enterprise value of approximately US$1.6 billion alongside a modest US$3.1M PIPE financing. The company is unprofitable, with approximately US$3.7M in trailing twelve-month revenue, and has seen its market capitalization decline to roughly US$162 million amid broader early-stage biotech investor caution, while pivoting commercially toward Bio Valley campuses in Johor and Kuala Lumpur, insurance and education verticals, and continued clinical validation of its NK cell pipeline.
ALPS Global Holding Berhad firmographics
Firmographics- Name
- ALPS Global Holding Berhad
- Legal name
- ALPS Global Holding Berhad
- Website
- https://alps-holdings.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ALPS Global Holding Berhad is a Kuala Lumpur-based integrated biotechnology group operating cell and gene therapy manufacturing (CelestiaLab), genomic testing (MyGenome), medical and wellness services, stem cell supplements, and healthcare financial solutions, serving individual patients, medical tourists, and institutional clients in Southeast Asia following its October 2025 Nasdaq listing.
- Ownership category
- akta.pro rank
ALPS Global Holding Berhad industry classification
Industry- Product category
- Biotechnology and Regenerative Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Food (Health) Supplement Retailers (456191)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Healthy Aging & Cognitive Support Supplements (CRADAGAM)
- akta.pro secondary industry
- Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)
Keywords
Where ALPS Global Holding Berhad is headquartered
LocationHeadquarters
- HQ city
- Kuala Lumpur
- HQ country
- Malaysia
- HQ region
- Asia
Offices2 records
Markets served
ALPS Global Holding Berhad business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Medical and Wellness Services: Revenue from medical centres, anti-aging clinics, health screening services, and aesthetic treatments
- Genomic Testing Services: Whole genome sequencing, mRNA testing, DNA testing services provided through MyGenome subsidiary
- Cellular Therapy Products: GMP-grade stem cell products including mesenchymal stem cells, dental pulp stem cells, and iPSCs for therapeutic applications
- Stem Cell Supplements: Célebre brand stem cell supplements for degenerative disease treatment, health improvement, and anti-aging
- Healthcare Financial Solutions: ALPSCap providing innovative healthcare with financial solutions to corporations, governments, and high-net-worth individuals
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
ALPS Global Holding Berhad product offering
Product offeringCore offering
ALPS is a fully-integrated biotechnology research, medical, and wellness services company that develops and delivers cellular therapies (mesenchymal stem cells, iPSCs, autologous NK cell therapy), genomic and molecular diagnostic testing (whole genome sequencing, mRNA, DNA testing), direct medical and aesthetic services through its medical centre, wellness and anti-aging services, stem cell supplements under the Célébre brand, and healthcare financial solutions via ALPSCap. Its vertically integrated platform spans cGMP-certified research, clinical development, commercialization, and supplementary wellness offerings.
Differentiator
Problem solved
Functional benefit
Brands
- CelestiaLab: Biotechnology company under ALPS specializing in Preventive Medicine to produce GMP-grade cellular products including mesenchymal stem cells, dental pulp stem cells and induced pluripotent stem cells for regenerative medicine
- MyGenome
- ALPS Medical Centre
- Célebre
- ALPSCap
- MontLife
- ALPS GlobeMedic
- Bio Valley
Products and services
- ALPS Medical Centre Services
- ALPS Wellness Centre and Medical Clinic (Genting Highlands)
- CelestiaLab Cellular Products
- MyGenome Genomic Testing Services
- Célébre Stem Cell Supplements
- ALPSCap Healthcare Financial Solutions
- MontLife Vaccine and Therapeutics Development
- Autologous NK Cell Therapy Cellular therapy service where a patient's own NK cells are purified from blood, cultured with cytokines for three weeks using ALPS' proprietary antibody-free culture protocol, and infused back to eliminate cancer cells and boost the immune system. Clinical safety, tolerability and effectiveness data published in SAGE Open Medical Case Reports.
Quantifiable outcome
- For early-stage cancer, cure rate can exceed 90-95%, but for advanced cancer it can drop to around 5%
- +2 more outcomes
Companies that use ALPS Global Holding Berhad
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
ALPS Global Holding Berhad technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ALPS Global Holding Berhad partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, minor and flagship.
- JLand Group (JohorCorp)corePartnership to build Bio Valley campus in Johor, Malaysia. The campus will be designed to house upstream research, mid-stream clinical studies, and downstream commercial activities to address gaps in Malaysia's biotech sector.
- Xiamen University MalaysiaminorMemorandum of Understanding signing for potential collaboration in research and education.
- HELP UniversityminorCourtesy visit to explore potential collaboration opportunity with ALPS in healthcare and wellness educational aspects.
- CanSino Biologics Inc. (CanSinoBIO)flagshipCanSinoBIO founders visited ALPS headquarters to explore potential strategic partnerships on medical research, clinical trial studies, and gene and cellular therapies. Discussions focused on precision and preventive medicine collaboration.
- IMU UniversityminorCourtesy visit to understand ALPS operations and explore potential strategic research collaboration and placement of medical/biotech students.
- AIMST UniversityminorCourtesy visit to explore potential strategic research collaboration and placement of AIMST University's PhD students in ALPS under supervision of ALPS' Chief Scientist.
- Shanghai Moge BiologyminorMalaysia ALPS Medical Center signed contract with Shanghai Moge Biology to jointly invest in construction of Huangshan Medical Healthcare industry, part of RCEP regional cooperation.
- Universiti Sains Malaysia (USM) - Institute of Advanced Medical and Dental Institute (IPPT)coreStrategic academia-industry collaboration establishing USM-ALPS Heart Research Laboratory. ALPS provided advanced equipment for cardiac cell and molecular research, supporting translational research with next-generation technology.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
ALPS Global Holding Berhad competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
ALPS Global Holding Berhad social profiles
Digital presenceALPS Global Holding Berhad financial estimates
Financial estimateRevenue estimate
Valuation estimate
ALPS Global Holding Berhad leadership team
Management profileNumber of profiles
Profiles4 records
ALPS Global Holding Berhad subsidiaries and ownership
Company hierarchySubsidiaries6 records
ALPS Global Holding Berhad funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ALPS Global Holding Berhad M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ALPS Global Holding Berhad
What does ALPS Global Holding Berhad do?
ALPS is a fully-integrated biotechnology research, medical, and wellness services company that develops and delivers cellular therapies (mesenchymal stem cells, iPSCs, autologous NK cell therapy), genomic and molecular diagnostic testing (whole genome sequencing, mRNA, DNA testing), direct medical and aesthetic services through its medical centre, wellness and anti-aging services, stem cell supplements under the Célébre brand, and healthcare financial solutions via ALPSCap. Its vertically integrated platform spans cGMP-certified research, clinical development, commercialization, and supplementary wellness offerings.
Is ALPS Global Holding Berhad a public or private company?
ALPS Global Holding Berhad is a public company. It is classified as public and is currently operating.
When was ALPS Global Holding Berhad founded?
ALPS Global Holding Berhad was founded in 2015. It employs 11 to 50 people.
Where is ALPS Global Holding Berhad based?
ALPS Global Holding Berhad is headquartered in Kuala Lumpur, Malaysia, in the Asia region.
How does ALPS Global Holding Berhad make money?
Five revenue lines are on record. Medical and Wellness Services are the primary driver. The others are genomic Testing Services, cellular Therapy Products, stem Cell Supplements and healthcare Financial Solutions.
Does ALPS Global Holding Berhad have an API?
No public API is recorded for ALPS Global Holding Berhad.
What industry is ALPS Global Holding Berhad in?
ALPS Global Holding Berhad's product category is Biotechnology and Regenerative Medicine. Its primary akta.pro industry code is CRADAGAM, Healthy Aging & Cognitive Support Supplements, with a secondary code of CRADAGAE, Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity). Its NAICS code is 541714 and its SIC code is 2834.